United Laboratories International Holdings Future Growth

Future criteria checks 1/6

United Laboratories International Holdings is forecast to grow earnings and revenue by 3.9% and 6.1% per annum respectively. EPS is expected to grow by 4% per annum. Return on equity is forecast to be 19.5% in 3 years.

Key information

3.9%

Earnings growth rate

4.0%

EPS growth rate

Pharmaceuticals earnings growth	11.1%
Revenue growth rate	6.1%
Future return on equity	19.5%
Analyst coverage	Good
Last updated	31 Oct 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

SZSC:3933 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	16,393	3,206	N/A	3,756	7
12/31/2025	15,382	3,015	N/A	3,545	8
12/31/2024	14,664	2,928	N/A	3,545	8
6/30/2024	14,009	2,908	1,420	3,088	N/A
3/31/2024	13,875	2,805	1,267	2,763	N/A
12/31/2023	13,740	2,701	1,114	2,439	N/A
9/30/2023	13,399	2,469	1,376	2,504	N/A
6/30/2023	13,059	2,236	1,637	2,568	N/A
3/31/2023	12,197	1,909	1,444	2,300	N/A
12/31/2022	11,334	1,581	1,251	2,031	N/A
9/30/2022	10,750	1,288	1,066	1,683	N/A
6/30/2022	10,166	995	882	1,336	N/A
3/31/2022	9,935	991	968	1,439	N/A
12/31/2021	9,703	988	1,055	1,543	N/A
9/30/2021	9,445	1,056	1,047	1,647	N/A
6/30/2021	9,187	1,123	1,039	1,752	N/A
3/31/2021	8,980	913	1,035	1,660	N/A
12/31/2020	8,772	703	1,030	1,568	N/A
9/30/2020	8,690	626	1,128	1,625	N/A
6/30/2020	8,607	549	1,226	1,683	N/A
3/31/2020	8,500	595	1,293	1,742	N/A
12/31/2019	8,393	642	1,361	1,801	N/A
9/30/2019	8,100	765	1,147	1,618	N/A
6/30/2019	7,808	888	932	1,436	N/A
3/31/2019	7,659	785	806	1,324	N/A
12/31/2018	7,511	683	681	1,213	N/A
9/30/2018	7,395	373	640	1,104	N/A
6/30/2018	7,280	64	599	995	N/A
3/31/2018	7,053	73	N/A	883	N/A
12/31/2017	6,827	82	N/A	770	N/A
9/30/2017	6,640	-34	N/A	957	N/A
6/30/2017	6,454	-150	N/A	1,144	N/A
3/31/2017	6,266	-211	N/A	1,109	N/A
12/31/2016	6,078	-272	N/A	1,074	N/A
9/30/2016	6,083	-216	N/A	976	N/A
6/30/2016	6,076	-159	N/A	875	N/A
3/31/2016	6,195	-32	N/A	1,182	N/A
12/31/2015	6,446	92	N/A	1,516	N/A
9/30/2015	6,597	148	N/A	1,522	N/A
6/30/2015	6,711	201	N/A	1,521	N/A
3/31/2015	6,565	373	N/A	1,460	N/A
12/31/2014	6,422	545	N/A	1,400	N/A
9/30/2014	6,179	552	N/A	1,436	N/A
6/30/2014	6,101	574	N/A	1,511	N/A
3/31/2014	6,112	306	N/A	1,347	N/A
12/31/2013	5,972	38	N/A	1,155	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3933's forecast earnings growth (3.9% per year) is above the savings rate (2.3%).

Earnings vs Market: 3933's earnings (3.9% per year) are forecast to grow slower than the Hong Kong market (11.7% per year).

High Growth Earnings: 3933's earnings are forecast to grow, but not significantly.

Revenue vs Market: 3933's revenue (6.1% per year) is forecast to grow slower than the Hong Kong market (7.8% per year).

High Growth Revenue: 3933's revenue (6.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 3933's Return on Equity is forecast to be low in 3 years time (19.5%).

United Laboratories International Holdings Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Recent updates

The United Laboratories International Holdings Limited Announces the Application for Marketing of Insulin Degludec Injection

First half 2024 earnings released: EPS: CN¥0.82 (vs CN¥0.71 in 1H 2023)

The United Laboratories International Holdings Limited Declares Interim Dividend for the Six Months Ended 30 June 2024

The United Laboratories International Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: CN¥1.49 (vs CN¥0.87 in FY 2022)

Investor sentiment improves as stock rises 16%

The United Laboratories International Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Less than half of directors are independent

New minor risk - Share price stability

The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection

the United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023

Investor sentiment deteriorates as stock falls 17%

The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection

First half 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.34 in 1H 2022)

the United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023

New major risk - Revenue and earnings growth

The United Laboratories International Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

Investor sentiment improves as stock rises 17%

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2022

Investor sentiment improves as stock rises 19%

Full year 2022 earnings released: EPS: CN¥0.87 (vs CN¥0.54 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

The United Laboratories International Holdings Limited Announces Approval of Marketing of Sodium Hyaluronate Eye Drops Applied by Zhuhai United Laboratories Co., Ltd

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 181,757,450 shares, representing 10% of its issued share capital, under the authorization approved on June 21, 2022.

The United Laboratories International Holdings Limited Announces an Interim Dividend for the Year 2022, Payable on 6 October 2022

The United Laboratories International Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2022

First half 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.34 in 1H 2021)

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2021, Payable on 20 July 2022

The United Laboratories International Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.40 in FY 2020)

Less than half of directors are independent

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 184,039,050 shares, representing 10% of its issued share capital, under the authorization approved on June 22, 2021.

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.34 (vs CN¥0.12 in 1H 2020)

The United Laboratories International Holdings Limited Announces Updated Information of the Group's Products

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.39 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.39 in FY 2019)

The United Laboratories International Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Investor sentiment improved over the past week

New 90-day low: HK$5.12

New 90-day low: HK$5.40

New 90-day low: HK$5.70

New 90-day low: HK$6.40

New 90-day low: HK$6.82

First half earnings released

Earnings released

New 90-day high - HK$8.66

The United Laboratories International Holdings Limited to Report First Half, 2020 Results on Aug 25, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies